Surgical surveillance in resource-poor settings
We congratulate the African Surgical Outcomes Study team, led by investi gators from lowincome and middle income countries, for quantifying the scale of global inequality in surgi cal care, and for providing measur able goals for future improvement efforts (April 21, p 1589). 1 This work also highlights the poor availability of the detailed information necessary to translate these inequalities into potential solutions. 2, 3 Continuous sur veillance systems or registries could provide such information but are notoriously challenging; dis parate paperbased systems, inadequate resources, and overburdened staff are seemingly insurmountable problems. [2] [3] [4] The Network for Improving Criti cal Care Systems and Training (NICST), which is based in lowincome and middleincome countries, is suc cess fully using settingadapted, electronic mobile platforms to close such gaps in the information available to care for acutely unwell patients. This clinician codesigned platform, which has been distributed in Pakistan and Sri Lanka, has been used in south Asia and has supported routine care for more than 114 785 patients. Real time dashboards enable clinicians to benefit from surveillance in daily decision making, 2,5 including manage ment of post operative compli cations. Aggregate data from more than 10 907 surgeries provide indicators of quality; these indicators include length of stay, unplanned admissions to intensive care units, and antibiotic use. The feasibility of use of this system is now being evaluated in Sierra Leone and Malawi. 
Healthier lives for all Africans
In their Commission, Irene Agyepong and colleagues (Dec 23, 2017, p 2803) 1 provide a comprehensive report on the pathway to healthier lives for all Africans by 2030. As highlighted in the Commission, we have been involved in training family physicians in Africa for the past 20 years within the frame work of the Primary Care and Family Medicine Education (Primafamed) network, a South-South cooperation that brings together family medicine, primary care, and public health in more than 20 African countries. 2 The participating departments interact electronically, share educational strat egies, develop distance learning, and build educational and research capacity through annual workshops, taking advantage of their African Journal for Primary Health Care and Family Medicine. The effects of the network have been documented, both in their development of depart ments and training programmes 3 and regarding their outcomes (namely, better access to and quality of care for local communities). 4 African family physicians can strengthen interdisciplinary primary healthcare teams in primary care facilities and within communities and, when appropriate, are involved as expert generalists in district hospitals.
All African countries are facing the challenge of scaling up avail ability of family physicians in primary health care to make quality health care accessible, particularly in urban slums and rural and remote areas. This accessibility requires a substantial proportion (40-60%) of graduates from medical schools in Africa to be trained for family medicine. 5 More integration between pri mary care and public health services will be needed to combine facility based and personcentred care with communitylevel responsiveness to popu lation needs, and to improve health outcomes. 6 In 2018, there is an urgent need for financial donors to fund interventions that strengthen the African primary healthcare system as a priority, rather than just investing in vertical diseaseorientated programmes, and to continue contributing to networks such as Primafamed. 
The hepatitis B epidemic in China should receive more attention
China's childhood hepatitis B virus (HBV) vaccination programme is a great public health success, resulting in a prevalence of HBsAg of only 1% in children under 5 years. However, the burden of HBV infection in China is still the highest in the world, with one third of the world's 240 million people with chronic HBV living in China. 1 Nevertheless, most people with HBV infection in China are unaware that they carry the disease, making HBV infection a truly silent epidemic. 2 Among the population with HBV infection in China, 28 million people require treatment, with 7 million of these being urgent because of advanced liver disease and the high risk of developing cancer. 2 However, less than one in 50 patients in need of treatment receive it, with the biggest barrier to treatment being affordability. 2 A 2016 study 3 sampled 4726 cases in China and revealed that the direct medical costs alone equalled 53·06% of the patient's annual household income. Six medications have been approved for the treatment of chronic HBV, but only lamivudine is included in the Chinese national drug list. 4 HBVrelated diseases have become an important cause of poverty and continue to perpetuate the cycle between poverty and illness in China.
Beyond the heavy economic burden, the discrimination attached to HBV infection remains a major problem in China. This can range from unwillingness to hug or shake hands with people with HBV infection, to losing a job or not being hired. Ignorance about the aspects of HBV is widespread, and many people believe that HBV can be transmitted through contact or by eating together. 5 In 2016, to implement healthrelated Sustainable Development Goals, the Healthy China 2030 plan was officially approved by China's Central Committee. By the end of 2017, 30 of 31 provinces, autonomous regions, and municipalities in China had also issued their local Healthy 2030 plans, and full sections of 22 of these plans can be accessed online. All the accessible plans make a statement on the control of communicable diseases. For AIDS, HIV, and tuberculosis, these plans emphasise health education, screening, diagnosis, treatment, and financial reimbursement. However, for HBV, these plans are still restricted to vaccination and prevention of mothertochild transmission, with five plans not even mentioning the word hepatitis. The attention paid to HBV is severely inadequate.
In China, the disease burden of HBV is the highest among communicable diseases, and about 10 million people living with chronic HBV will die by 2030, 2 with most of these deaths being avoidable. The HBV immunisation programme is a great public health success story, but efforts to address other HBVrelated problems are lagging behind. To really achieve the Healthy China 2030 goals, China should also mobilise a response to HBV on a scale similar to that of other communicable diseases, such as HIV, AIDS, and tubercu losis, including enhanced education, elimination of discrimination, en hanced screening, and the offer of affordable and effective treatment to patients.
